Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACOG NASDAQ:ARTV NASDAQ:BTAI NASDAQ:CRDF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$6.87-1.7%$7.92$3.75▼$11.54$146.11M2.63107,662 shs24,592 shsARTVArtiva Biotherapeutics$5.41+11.8%$3.13$1.47▼$15.49$132.15M2.836.43 million shs992,970 shsBTAIBioXcel Therapeutics$2.33+3.1%$3.27$1.17▼$13.28$36.18M0.181.11 million shs781,187 shsCRDFCardiff Oncology$2.23+0.9%$2.16$1.90▼$5.64$147.02M1.62829,495 shs737,041 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition-1.72%+1.03%-14.13%-31.09%+686,999,900.00%ARTVArtiva Biotherapeutics+11.78%-9.98%+87.85%+50.28%-50.59%BTAIBioXcel Therapeutics+3.10%+0.87%-9.69%+28.73%-74.87%CRDFCardiff Oncology+0.90%+1.83%+7.73%-43.83%-22.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$6.87-1.7%$7.92$3.75▼$11.54$146.11M2.63107,662 shs24,592 shsARTVArtiva Biotherapeutics$5.41+11.8%$3.13$1.47▼$15.49$132.15M2.836.43 million shs992,970 shsBTAIBioXcel Therapeutics$2.33+3.1%$3.27$1.17▼$13.28$36.18M0.181.11 million shs781,187 shsCRDFCardiff Oncology$2.23+0.9%$2.16$1.90▼$5.64$147.02M1.62829,495 shs737,041 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition-1.72%+1.03%-14.13%-31.09%+686,999,900.00%ARTVArtiva Biotherapeutics+11.78%-9.98%+87.85%+50.28%-50.59%BTAIBioXcel Therapeutics+3.10%+0.87%-9.69%+28.73%-74.87%CRDFCardiff Oncology+0.90%+1.83%+7.73%-43.83%-22.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACOGAlpha Cognition 3.00Buy$18.00162.01% UpsideARTVArtiva Biotherapeutics 2.60Moderate Buy$18.25237.34% UpsideBTAIBioXcel Therapeutics 2.43Hold$39.751,606.01% UpsideCRDFCardiff Oncology 2.50Moderate Buy$10.63376.46% UpsideCurrent Analyst Ratings BreakdownLatest BTAI, ARTV, CRDF, and ACOG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/24/2025BTAIBioXcel TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/24/2025CRDFCardiff OncologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/20/2025ACOGAlpha CognitionHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $18.0010/17/2025ARTVArtiva BiotherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$18.00 ➝ $23.0010/17/2025ARTVArtiva BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.0010/8/2025ARTVArtiva BiotherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025BTAIBioXcel TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025CRDFCardiff OncologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ARTVArtiva BiotherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025BTAIBioXcel TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025CRDFCardiff OncologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACOGAlpha CognitionN/AN/AN/AN/A$2.59 per shareN/AARTVArtiva BiotherapeuticsN/AN/AN/AN/A$7.68 per shareN/ABTAIBioXcel Therapeutics$2.27M16.43N/AN/A($30.01) per share-0.08CRDFCardiff Oncology$680K218.18N/AN/A$1.86 per share1.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACOGAlpha Cognition-$14.64M-$1.60N/A∞N/AN/A-80.16%-60.95%11/13/2025 (Estimated)ARTVArtiva Biotherapeutics-$65.37M-$2.62N/AN/AN/AN/A-42.60%-37.76%11/11/2025 (Estimated)BTAIBioXcel Therapeutics-$59.60M-$12.64N/AN/AN/A-5,869.82%N/A-134.45%11/13/2025 (Estimated)CRDFCardiff Oncology-$45.43M-$0.87N/AN/AN/A-9,344.14%-77.94%-63.65%11/6/2025 (Estimated)Latest BTAI, ARTV, CRDF, and ACOG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025ACOGAlpha Cognition-$0.46N/AN/AN/A$3.21 millionN/A11/13/2025Q3 2025BTAIBioXcel Therapeutics-$1.54N/AN/AN/A$0.20 millionN/A11/11/2025Q3 2025ARTVArtiva Biotherapeutics-$0.90N/AN/AN/AN/AN/A11/6/2025Q3 2025CRDFCardiff Oncology-$0.20N/AN/AN/A$0.12 millionN/A8/14/2025Q2 2025ACOGAlpha Cognition-$0.46-$0.65-$0.19-$0.65$2.32 million$1.66 million8/12/2025Q2 2025BTAIBioXcel Therapeutics-$2.30-$2.45-$0.15-$2.45$0.21 million$0.12 million8/6/2025Q2 2025ARTVArtiva Biotherapeutics-$0.84-$0.87-$0.03-$0.87N/AN/A7/29/2025Q2 2025CRDFCardiff Oncology-$0.19-$0.21-$0.02-$0.21$0.11 million$0.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACOGAlpha CognitionN/AN/AN/AN/AN/AARTVArtiva BiotherapeuticsN/AN/AN/AN/AN/ABTAIBioXcel TherapeuticsN/AN/AN/AN/AN/ACRDFCardiff OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACOGAlpha CognitionN/A17.1416.83ARTVArtiva BiotherapeuticsN/A13.8413.84BTAIBioXcel TherapeuticsN/A0.760.74CRDFCardiff OncologyN/A4.424.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACOGAlpha CognitionN/AARTVArtiva BiotherapeuticsN/ABTAIBioXcel Therapeutics30.68%CRDFCardiff Oncology16.29%Insider OwnershipCompanyInsider OwnershipACOGAlpha Cognition14.00%ARTVArtiva Biotherapeutics21.40%BTAIBioXcel Therapeutics21.20%CRDFCardiff Oncology7.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACOGAlpha CognitionN/A20.90 million17.98 millionN/AARTVArtiva Biotherapeutics8124.43 million19.20 millionN/ABTAIBioXcel Therapeutics9016.01 million12.62 millionOptionableCRDFCardiff Oncology2066.53 million61.40 millionOptionableBTAI, ARTV, CRDF, and ACOG HeadlinesRecent News About These CompaniesCardiff Oncology: Preparing For A Defining 20261 hour ago | seekingalpha.comCardiff Oncology's Promising Cancer Breakthrough Ahead - Why I Choose To BuyOctober 22 at 8:03 AM | seekingalpha.comBlair William & Co. IL Grows Position in Cardiff Oncology, Inc. $CRDFOctober 12, 2025 | marketbeat.comWeiss Ratings Reiterates "Sell (D-)" Rating for Cardiff Oncology (NASDAQ:CRDF)October 9, 2025 | marketbeat.comCardiff Oncology, Inc. (NASDAQ:CRDF) Receives Average Rating of "Moderate Buy" from AnalystsOctober 3, 2025 | marketbeat.comCardiff Oncology to Participate in Two Upcoming Investor ConferencesOctober 2, 2025 | globenewswire.comCardiff Oncology to Participate in Three Upcoming Investor ConferencesAugust 28, 2025 | globenewswire.comGary W. Pace Buys 15,000 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) StockAugust 1, 2025 | insidertrades.comCardiff Reports 49% Response Rate With Onvansertib in RAS-Mutated Colorectal CancerJuly 31, 2025 | appliedclinicaltrialsonline.comACardiff Oncology Insiders Land Bargain With Gains Of US$244kJuly 31, 2025 | finance.yahoo.comCardiff Oncology Reports Second Quarter 2025 Results and Provides Business UpdateJuly 31, 2025 | finance.yahoo.comCardiff Oncology (CRDF) Q2 Loss Down 19%July 30, 2025 | fool.comWhy Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?July 30, 2025 | benzinga.comCardiff Oncology: Data Update Resolves Some SignalsJuly 30, 2025 | seekingalpha.comCardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue EstimatesJuly 29, 2025 | zacks.comCardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)July 29, 2025 | globenewswire.comCardiff Oncology: Volatility Afoot With Onvansertib Update Near-TermJuly 18, 2025 | seekingalpha.comLadenburg Thalmann Initiates Coverage of Cardiff Oncology (CRDF) with Buy RecommendationJuly 9, 2025 | msn.comWhile institutions invested in Cardiff Oncology, Inc. (NASDAQ:CRDF) benefited from last week's 16% gain, retail investors stood to gain the mostJuly 3, 2025 | finance.yahoo.comCRDF - Cardiff Oncology Inc Ownership - MorningstarJuly 2, 2025 | morningstar.comMCardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low OpportunityJune 27, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBTAI, ARTV, CRDF, and ACOG Company DescriptionsAlpha Cognition NASDAQ:ACOG$6.87 -0.12 (-1.72%) As of 10/24/2025 04:00 PM EasternAlpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.Artiva Biotherapeutics NASDAQ:ARTV$5.41 +0.57 (+11.78%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$5.20 -0.21 (-3.88%) As of 10/24/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.BioXcel Therapeutics NASDAQ:BTAI$2.33 +0.07 (+3.10%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$2.34 +0.00 (+0.21%) As of 10/24/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.Cardiff Oncology NASDAQ:CRDF$2.23 +0.02 (+0.90%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$2.24 +0.01 (+0.45%) As of 10/24/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
